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Introduction
The recent successes of genome-wide association studies 
and the promises of whole genome sequencing fuel 
interest in the translation of this new wave of basic 
genetic knowledge to health care practice. Knowledge 
about genetic risk factors may be used to target 
diagnostic, preventive, and therapeutic interventions for 
com plex disorders based on a person’s genetic risk, or to 
complement existing risk models based on classical non-
genetic factors, such as the Framingham risk score for 
cardiovascular disease. Implementation of genetic risk 
prediction in health care requires a series of studies that 
encompass all phases of translational research [1,2], 
starting with a comprehensive evaluation of genetic risk 
prediction.
With increasing numbers of discovered genetic 
markers that can be used in future genetic risk prediction 
studies, it is crucial to enhance the quality of the 
reporting of these studies, since valid interpretation 
could be compromised by the lack of reporting of key 
information. Information that is often missing includes 
details in the description of how the study was designed 
and conducted (for example, how genetic variants were 
selected and coded, how risk models or genetic risk 
scores were constructed, and how risk categories were 
chosen), or how the results should be interpreted. An 
appropriate assessment of the study’s strengths and 
weak nesses is not possible without this information. 
There is ample evidence that prediction research often 
suffers from poor design and bias, and these may also 
have an impact on the results of the studies and on 
models of disease outcomes based on these studies [3-5]. 
Although most prognostic studies published to date 
claim significant results [6,7], very few translate to 
clinically useful applications. Just as for observational 
epidemiological studies [8], poor reporting complicates 
the use of the specific study for research, clinical, or 
public health purposes and hampers the synthesis of 
evidence across studies.
Reporting guidelines have been published for various 
research designs [9], and these contain many items that 
are also relevant to genetic risk prediction studies. In 
particular, the guidelines for genetic association studies 
(STrenghtening the REporting of Genetic Association 
studies - STREGA) have relevant items on the assessment 
of genetic variants, and the guidelines for observational 
studies (Strengthening the Reporting of OBservational 
studies in Epidemiology - STROBE) have relevant items 
about the reporting of study design. The guidelines for 
diagnostic studies (STAndards for Reporting Diagnostic 
accuracy - STARD) and those for tumor marker prog-
nostic studies (Reporting of tumor MARKer studies  - 
REMARK) include relevant items about test evaluation; 
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the REMARK guidelines also have relevant items about 
risk prediction [10-13]. However, none of these guidelines 
are fully suited to genetic risk prediction studies, an 
emerging field of investigation with specific methodo-
logical issues that need to be addressed, such as the 
handling of large numbers of genetic variants (from tens 
to tens of thousands) and flexibility in handling such 
large numbers in analyses. We organized a two-day 
workshop with an international group of risk prediction 
researchers, epidemiologists, geneticists, methodologists, 
statisticians, and journal editors to develop recom-
mendations for the reporting of genetic risk prediction 
studies - the GRIPS statement.
Genetic	risk	prediction	studies
Genetic risk prediction studies typically develop or 
validate models that predict the risk of disease, but they 
are also being investigated for use in predicting prog nostic 
outcome, treatment response, or treatment-related harms. 
Risk prediction models are statistical algorithms, which 
may be simple genetic risk scores (for example, risk allele 
counts), may be based on regression analyses (for example, 
weighted risk scores or predicted risks), or may be based 
on more complex analytic approaches, such as support 
vector machine learning or classification trees. The risk 
models may be based on genetic variants only, or include 
both genetic and non-genetic risk factors [14].
Aims	and	use	of	the	GRIPS	statement
The 25 items of the GRIPS statement are intended to 
maximize the transparency, quality, and completeness of 
reporting on research methodology and findings in a 
particular study. It is important to emphasize that these 
recommendations are guidelines only for how to report 
research and do not prescribe how to perform genetic 
risk prediction studies. The guidelines do not support or 
oppose the choice of any particular study design or 
method; for example, the guidelines recommend that the 
study population should be described, but do not specify 
which population is preferred in a particular study.
The intended audience for the reporting guidelines is 
broad and includes epidemiologists, geneticists, statis-
ticians, clinician scientists, and laboratory-based investi-
gators who undertake genetic risk prediction studies, as 
well as journal editors and reviewers who have to appraise 
the design, conduct and analysis of such studies. In 
addition, it includes ‘users’ of such studies who wish to 
understand the basic premise, design, and limitations of 
genetic prediction studies in order to interpret the results 
for their potential application in health care. These 
guidelines are also intended to ensure that essential data 
from future genetic risk prediction studies are presented in 
standardized form, which will facilitate information 
synthesis as part of systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide 
array of risk prediction studies, because GRIPS focuses 
on the main aspects of the design and analysis of risk 
prediction studies. GRIPS does not address randomized 
trials that may be performed to test risk models, nor does 
it specifically address decision analyses, cost-effectiveness 
analyses, assessment of health care needs, or assessment 
of barriers to health care implementation [15]. Once the 
performance of a risk model has been established, these 
next steps toward implementation require further 
evaluation [10,16]. For the reporting of these studies, 
which go beyond the assessment of genetic risk models 
as such, additional requirements apply. However, proper 
documentation of genetic predictive research according 
to GRIPS might facilitate the translation of research 
findings into clinical and public health practice.
Development	of	the	GRIPS	statement
The GRIPS statement was developed by a multidiscipli-
nary panel of 25 risk prediction researchers, epidemio-
logists, geneticists, methodologists, statisticians, and 
journal editors, seven of whom were also part of the 
STREGA initiative [11]. They attended a two-day meeting 
in Atlanta, Georgia (US) in December 2009 that was 
sponsored by the US Centers for Disease Control and 
Prevention on behalf of the Human Genome Epidemio-
logy Network (HuGENet) [17]. Participants discussed a 
draft version of the guidelines that was prepared and 
distributed before the meeting. This draft version was 
developed on the basis of existing reporting guidelines, 
namely STREGA [11], REMARK [13], and STARD [12]. 
These were selected out of all available guidelines [18] 
because of their focus on observational study designs and 
genetic factors (STREGA), prediction models (REMARK), 
and test evaluation (REMARK and STARD). During the 
meeting, methodological issues pertinent to risk predic-
tion studies were addressed in presentations. Workshop 
participants were asked to change, combine, or delete 
proposed items and add additional items if necessary. 
Participants had extensive post-meeting electronic corres-
pondence. To harmonize our recommendations for 
genetic risk prediction studies with previous guidelines, 
we chose the same wording for the items wherever 
possible. Finally, we tried to create consistency with 
previous guidelines for the evaluation of risk prediction 
studies of cardiovascular diseases and cancer [2,19]. The 
final version of the checklist is presented in Table 1.
The	GRIPS	explanation	and	elaboration	article
Accompanying this GRIPS statement, an Explanation 
and Elaboration document has been written [20], 
modeled after those developed for other reporting 
guidelines [21-24]. The Explanation and Elaboration docu-
ment illustrates each item with at least one published 
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Table	1.	Reporting	recommendations	for	evaluation	of	risk	prediction	models	that	include	genetic	variants
Title and abstract 1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the 
   abstract: genetic or genomic, risk, prediction
  
Introduction  
 Background and rationale 2 Explain the scientific background and rationale for the prediction study
 Objectives 3 Specify the study objectives and state the specific model(s) that is/are investigated. State if the study concerns  
   the development of the model(s), a validation effort, or both
  
Methods  
 Study design and setting 4* Specify the key elements of the study design and describe the setting, locations, and relevant dates, including  
   periods of recruitment, follow-up, and data collection
 Participants 5* Describe eligibility criteria for participants, and sources and methods of selection of participants
 Variables: definition 6* Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using a  
   widely used nomenclature system
 Variables: assessment 7* (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a  
   detailed description of genotyping and other laboratory methods
 Variables: coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were 
   handled in the analyses. If applicable, describe which groupings were chosen, and why
 Analysis: risk model 9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables  
 construction  were initially examined or considered for inclusion in models. Include details of any variable selection procedures 
   and other model-building issues. Specify the horizon of risk prediction (for example, 5-year risk)
 Analysis: validation 10 Specify the procedure and data used for the validation of the risk model
 Analysis: missing data 11 Specify how missing data were handled
 Analysis: statistical methods 12 Specify all measures used for the evaluation of the risk model, including, but not limited to, measures of model fit 
   and predictive ability
 Analysis: other 13 Describe all subgroups, interactions, and exploratory analyses that were examined
  
Results  
 Participants 14* Report the numbers of individuals at each stage of the study. Give reasons for non-participation at each stage.  
   Report the number of participants not genotyped, and reasons why they were not genotyped
 Descriptives: population 15* Report demographic and clinical characteristics of the study population, including risk factors used in the risk  
   modeling
 Descriptives: model estimates 16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted  
   estimates and their precision from the full risk model(s) for each variable
 Risk distributions 17* Report distributions of predicted risks and/or risk scores
 Assessment 18 Report measures of model fit and predictive ability, and any other performance measures, if pertinent
 Validation 19 Report any validation of the risk model(s)
 Other analyses  20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent
  
Discussion  
 Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of  
   participants, and measurements and analyses, and discuss their impact on the results of the study
 Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from  
   similar studies, and other relevant evidence
 Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results
  
Other
 Supplementary information 24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly  
   available and, if so, how they can be accessed
 Funding 25 Give the source of funding and the role of the funders for the present study. State whether there are any conflicts 
   of interest
Items marked with an asterisk should be reported for every population in the study.
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example that we consider transparent in reporting, 
explains the rationale for its inclusion in the checklist, 
and presents details of the items that need to be 
addressed to ensure transparent reporting. The Expla na-
tion and Elaboration document was produced after the 
meeting. The document was prepared by a small 
subgroup and shared with all workshop participants for 
additional revisions and final approval.
Conclusions	and	future	directions
High-quality reporting reveals the strengths and weak-
nesses of empirical studies, facilitates the interpretation 
of the scientific and health care relevance of the results - 
especially within the framework of systematic reviews 
and meta-analyses - and helps build a solid evidence base 
for moving genomic discoveries into applications in 
health care practice. The GRIPS guidelines were developed 
to improve the transparency, quality and completeness of 
the reporting of genetic risk prediction studies. As 
outlined in the introduction, GRIPS does not prescribe 
how studies should be designed, conducted, or analyzed, 
and therefore the guidelines should not be used to assess 
the quality of empirical studies [25]. The guidelines 
should be used only to check whether all essential items 
are adequately reported.
Finally, the methodology for designing and assessing 
genetic risk prediction models is still developing. For 
example, newer measures of reclassification were first 
intro duced in 2007 [26], and several alternative reclassi fi-
ca tion measures have been proposed [27]. Which 
measures to apply and when to use measures of re-
classification are still subject to ongoing evaluation and 
discussion [28]. Furthermore, alternative strategies for 
constructing risk models other than simple regression 
analyses are being explored, and these may add increased 
complexity to the reporting. In formulating the items of 
the GRIPS statement, these methodological advances 
were anticipated. It is for this reason that the GRIPS 
statement recommends how a study should be reported 
and not how a study should be conducted or analyzed. 
Therefore, methodological and analytical developments 
will not immediately impact the validity and relevance of 
the items, but the GRIPS statement will be updated when 
this is warranted by essential new developments in the 
construction and evaluation of genetic risk models.
Co-publication
In order to encourage dissemination of the GRIPS state-
ment, this article will also be published by PLoS Medicine, 
Annals of Internal Medicine, BMJ, Circulation: Cardio­
vascular Genetics, European Journal of Clinical Investiga­
tion, European Journal of Epidemiology, European Journal 
of Human Genetics, Genetics in Medicine, Genome 
Medicine, and Journal of Clinical Epidemiology.
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